Document resource
Background and Importance Biological treatments used in severe asthma aim to reduce exacerbations, usually defined as emergency visits/hospitalisations and/or the use of systemic corticosteroids, whose consumption associated with the appearance of significant adverse events. More real-life studies are needed to determine what OGC reduction these biologics produce.Aim and objectives To evaluate the effectiveness of biologics in patients with severe uncontrolled asthma (SUCA) in terms of reducing OGC consumption.Material and methods A retrospective observational study was carried out on patients with SUCA on biological treatments (omalizumab, mepolizumab, benralizumab and/or dupilumab) who had been on treatment for at least 1 year in our hospital. If they had received more than one biologic, the last treatment was analysed. Baseline OGC consumption was retrospectively collected during the 12 months prior to the start of the biological and compared with the consumption of 12 months later. This data was obtained from microstrategy application, expressed as defined daily doses (DDD) consumed during 1 year, corresponding to the dispensations carried out in the pharmacy. The variable analysed was the percentage of dose reductions and/or interruptions of OGC treatment.Results 62 patients were included, of whom 27 were excluded for not completing 1 year of biological therapy. 35 patients met the study criteria and were analysed: 14 mepolizumab (40%), nine benralizumab (26%), six dupilumab (17%), and six omalizumab (17%). The average DDD of OGC received was 18.3 (2-182) mg. A total of 24 patients required baseline OGC, 12 of these patients (50%) were able to discontinue treatment and five patients (20.8%) reduced the dose. The biologic that achieved the greatest number of discontinuations and/or dose reductions was benralizumab (35.3%), followed by mepolizumab (29.4%), dupilumab (17.6%) and omalizumab (17.6%). Of the 35 patients, 22 (62.9%) did so in first-line (15 were corticosteroid dependent) and 13 (37.1%) in second or subsequent lines (nine corticosteroid dependent). The percentage of dose reduction and/or suspension of OGC among first-line corticosteroid dependents was: benralizumab (40%), omalizumab (30%), dupilumab (20%) and mepolizumab (10%). While the patients in second or successive lines: mepolizumab (57.1%), benralizumab (28.6%) and dupilumab (14.3%), there were no patients with omalizumab.Conclusion and Relevance 70.8% of corticosteroid dependent patients managed to reduce or interrupt treatment with OGC, which confirms, in our sample, the relevant effectiveness of biological treatments in reducing dependence on OGC.Conflict of Interest No conflict of interest